LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
12 November 2021 - 2:08AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
biotechnology company, today announced that LAVA and The Antibody
Society, a non-profit association, are co-organizing a virtual
symposium Emerging cancer therapies leveraging gamma-delta effector
T cells taking place on Mon., Nov. 29, 2021 from 11 a.m. to 2 p.m.
EST / 17.00 to 20.00 CET.
The symposium will focus on the emerging
landscape of technologies leveraging gamma delta T cells for
anticancer therapeutics and will be moderated by Andrea van Elsas,
Ph.D., chair, scientific advisory board at LAVA, and will feature
presentations from leading experts in the field of gamma
delta T cell immunity.
- Prof. Hans van der Vliet, M.D.,
Ph.D., professor, medical oncology, Amsterdam UMC and chief
scientific officer, LAVA Therapeutics
- Prof. Daniel Olive, M.D., Ph.D.,
head of the immunity and cancer lab, Cancer Research Center of
Marseille; professor, immunology and director, oncology research
programs, Aix Marseille University; scientific founder and chairman
of the board, ImCheck Therapeutics
- Prof. Jürgen Kuball, M.D., Ph.D.,
head of the department of hematology, UMC Utrecht; co-founder,
Gadeta
- Michael Koslowski, M.D., chief
medical officer, head of research and development, GammaDelta
Therapeutics
The presentations will be followed by a panel
discussion where the speakers will be joined by two renowned key
opinion leaders in immuno-oncology:
- Prof. Padmanee Sharma, M.D., Ph.D.,
professor, departments of genitourinary medical oncology and
immunology and scientific director, immunotherapy platform,
University of Texas MD Anderson Cancer Center; co-director of
the Parker Institute for Cancer Immunotherapy, MD Anderson Cancer
Center
- Prof. James Allison, M.D., Ph.D.,
regental professor, chair, department of immunology, the Olga Keith
Wiess Distinguished University Chair for Cancer Research, director
of the Parker Institute for Cancer Research, executive director of
the immunotherapy platform, MD Anderson Cancer Center; Nobel
laureate
“As the unique anti-cancer properties of gamma
delta T cells become better understood, we expect there to be
increasing efforts to leverage this unique cell population for
anti-cancer therapeutics,” said Paul W.H.I. Parren, Ph.D.,
executive vice president, head of research and development, LAVA
Therapeutics; board member, The Antibody Society. “We are very
excited to help organize such an exciting event with a remarkable
group to discuss various ways to unlock the potential of these
cells.”
To view the agenda and register for the free,
virtual symposium, please visit The Antibody Society.
Access to the recording will be available under
the "Events" tab on the investor relations section of the LAVA
Therapeutics website at:
https://ir.lavatherapeutics.com/news-events/events
About The Antibody SocietyThe
Antibody Society is an international non-profit trade association
representing individuals and organizations involved in antibody
research and development. The Society is an authoritative source of
information about antibody therapeutics development, which is
disseminated via our website, presentations and publications. In
addition, the Society organizes conferences and webinars on
antibody research and development and related topics. The Society
also serves as the home for the Adaptive Immune Receptor Repertoire
Community, which focuses on developing standards and protocols for
curating, analyzing and sharing antibody B and T cell receptors. As
a business association, the Society can engage with government and
international agencies such as the World Health Organization to
discuss topics that are important to the antibody community, such
as international naming conventions. For more information, please
visit: https://www.antibodysociety.org/ and follow us on LinkedIn
and Twitter.
About LAVA TherapeuticsLAVA
Therapeutics N.V. is a clinical-stage biotechnology company
utilizing its proprietary Gammabody™ platform to develop a
portfolio of bispecific gamma delta T cell engagers (gamma delta
bsTCEs) for the potential treatment of solid tumors and
hematological malignancies. The company’s innovative approach
utilizes bispecific antibodies engineered to selectively kill
cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector
functions upon cross-linking to tumor associated antigens. A Phase
1/2a clinical study evaluating LAVA-051 in patients with certain
hematological malignancies is currently enrolling (NCT04887259).
The company currently anticipates data from the Phase 1 dose
escalation phase of the study in the first half of 2022 with top
line clinical data from the Phase 2a expansion cohorts expected in
the second half of 2022. The company plans to initiate a Phase 1/2a
clinical study to evaluate LAVA-1207 in patients with prostate
cancer in the fourth quarter of 2021. For more information, please
visit www.lavatherapeutics.com and follow us on LinkedIn and
Twitter.
LAVA’s Cautionary Note on
Forward-Looking StatementsThis press release contains
forward-looking statements, including in respect of the company’s
anticipated growth and clinical developments plans, including the
timing of clinical trials. Words such as “anticipate,” “believe,”
“could,” “will,” “may,” “expect,” “should,” “plan,” “intend,”
“estimate,” “potential” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on LAVA’s expectations
and assumptions as of the date of this press release and are
subject to various risks and uncertainties that may cause actual
results to differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the preclinical data,
clinical development and scope of clinical trials, and the
potential use of our product candidates to treat various tumor
targets. Many factors, risks and uncertainties may cause
differences between current expectations and actual results
including, among other things, the timing and results of our
research and development programs and preclinical and clinical
trials, our ability to obtain regulatory approval for and
commercialize our product candidates, our ability to leverage our
initial programs to develop additional product candidates using our
GammabodyTM platform, and the failure of LAVA’s collaborators to
support or advance collaborations or our product candidates. In
addition, the COVID-19 pandemic may disrupt our business and that
of the third parties on which we depend, including delaying or
otherwise disrupting our clinical trials and preclinical studies,
manufacturing and supply chain, or impairing employee productivity.
LAVA assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
CONTACTS
Edward SmithChief Financial Officerir@lavatherapeutics.com
Catherine
Day+1-917-763-2709Catherine@newdaybioconsulting.com
Janice ReichertExecutive Director, The Antibody
Societyjanice.reichert@antibodysociety.org
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ba028e4e-bc5e-40a9-9438-f767a973f8e7
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024